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Abstract
Background: Recently, several new endoscopic treatments have been used to treat patients with Barrett’s
esophagus with high grade dysplasia. This systematic review aimed to determine the safety and effectiveness of
these treatments compared with esophagectomy.
Methods: A comprehensive literature search was undertaken to identify studies of endoscopic treatments for
Barrett’s esophagus or early stage esophageal cancer. Information from the selected studies was extracted by two
independent reviewers. Study quality was assessed and information was tabulated to identify trends or patterns.
Results were pooled across studies for each outcome. Safety (occurrence of adverse events) and effectiveness
(complete eradication of dysplasia) were compared across different treatments.
Results: The 101 studies that met the selection criteria included 8 endoscopic techniques and esophagectomy;
only 12 were comparative studies. The quality of evidence was generally low. Methods and outcomes were
inconsistently reported. Protocols, outcomes measured, follow-up times and numbers of treatment sessions varied,
making it difficult to calculate pooled estimates.
The surgical mortality rate was 1.2%, compared to 0.04% in 2831 patients treated endoscopically (1 death). Adverse
events were more severe and frequent with esophagectomy, and included anastomotic leaks (9.4%), wound infec-
tions (4.1%) and pulmonary complications (4.1%). Four patients (0.1%) treated endoscopically experienced bleeding
requiring transfusions. The stricture rate with esophagectomy (5.3%) was lower than with porfimer sodium photo-
dynamic therapy (18.5%), but higher than aminolevulinic acid (ALA) 60 mg/kg PDT (1.4%). Dysphagia and odyno-
phagia varied in frequency across modalities, with the highest rates reported for multipolar electrocoagulation
(MPEC). Photosensitivity, an adverse event that occurs only with photodynamic therapy, was experienced by 26.4%
of patients who received porfimer sodium.
Some radiofrequency ablation (RFA) or argon plasma coagulation (APC) studies (used in multiple sessions) reported
rates of almost 100% for complete eradication of dysplasia. But the study methods and findings were not ade-
quately described. The other studies of endoscopic treatments reported similarly high rates of complete
eradication.
Conclusions: Endoscopic treatments offer safe and effective alternatives to esophagectomy for patients with
Barrett’s esophagus and high grade dysplasia. Unfortunately, shortcomings in the published studies make it
impossible to determine the comparative effectiveness of each of the endoscopic treatments.
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Barrett’s esophagus (BE) is a benign condition where
abnormal cells (intestinal metaplasia), replace the nor-
mal lining of the esophagus. It is typically caused by
long-term gastroesophageal reflux disease. Between 2%
to 6% of Canadians may have Barrett’s esophagus [1].
Similar prevalence rates have been reported in studies
from Sweden (1.6%) and the United States (5.9%) [2,3].
Although Barrett’s esophagus itself is not harmful, in
some individuals, precancerous dysplasia develops in the
Barrett’s tissue. The presence of dysplasia carries a
higher risk of developing esophageal adenocarcinoma -
a type of esophageal cancer. In addition to the cancer
risk, Barrett’s esophagus decreases patients’ quality of
life and increases health care costs [4-7].
The rising incidence of esophageal adenocarcinoma
has focused attention on preventing cancer by removing
the dysplasia and allowing normal, squamous esophageal
mucosa to regenerate. Endoscopic techniques have been
developed as a result. They can be applied sequentially
to increase diagnostic yield and improve treatment out-
comes. There are two categories: endoscopic mucosal
resection (EMR) and endoscopic ablation. EMR with a
cautery snare excision technique can remove visible
raised or flat lesions for diagnostic and therapeutic
roles. Diagnostically, it allows for complete histopatholo-
gical assessment of the target mucosa. Those with
superficial lesions can go on to further ablative techni-
ques. Lesions that are found to invade submucosa may
need referral for surgical resection. Therapeutically,
EMR can be used for curative intent if the target lesion
is small. However, in most cases of Barrett’s esophagus,
it is used to remove dysplastic nodules leaving the larger
surface area for endoscopic ablation.
Photodynamic therapy (PDT) is one of the new endo-
scopic treatments used to remove dysplasia. Other endo-
scopic treatments include: argon plasma coagulation
(APC), cryoablation, laser ablation, multipolar electro-
coagulation (MPEC), radiofrequency ablation (RFA), and
thermocoagulation. Depending on the extent of dyspla-
sia, several endoscopic treatment sessions or a combina-
tion of treatments may be used.
Patients also receive long-term drug therapy to control
gastroesophageal reflux and prevent further damage to the
esophagus [8]. Endoscopic therapies are less invasive alter-
natives to esophagectomy (surgical removal of the esopha-
gus), which is associated with high rates of morbidity and
mortality, and with decreased quality of life [9-11].
Clinicians now have a variety of technologies to choose
from when treating Barrett’s esophagus with dysplasia.
This systematic review of published clinical studies com-
pares the evidence on the safety and effectiveness of the
endoscopic treatments and of esophagectomy and may
provide some guidance for clinical practice.
Methods
Data collection
Literature search
An extensive search for published and unpublished stu-
dies of endoscopic and non-endoscopic procedures for
Barrett’s esophagus was performed. Search terms
included keywords and controlled vocabulary terms
used to describe Barrett’s, photodynamic therapy and
other endoscopic techniques, and esophagectomy.
Searches for the alternative treatments (i.e., other than
PDT) were limited to studies from 2003 to January
2009. The bibliographic databases searched included:
PubMed (MEDLINE), The Cochrane Library, the UK
Centre for Reviews and Dissemination (DARE, Health
Technology Assessment, and NHS Economic Evalua-
tion) databases, EMBASE, CINAHL, Web of Science
and EconLit. Monthly update searches in PubMed were
run throughout the project to identify new studies.
Meeting abstracts from the American Society of Clinical
Oncology and Digestive Disease Week, as well as prac-
tice guidelines and clinical trials web sites were also
searched, as were the reference lists from relevant
papers and earlier health technology assessments.
Study selection
Results from the literature searches were imported into
a Reference Manager® database to remove duplicates
and manage bibliographic citations. Titles and abstracts
(where available), were independently screened by two
researchers. The full papers of potentially relevant stu-
dies were retrieved and assessed against pre-defined
inclusion criteria (Table 1). Non-English language stu-
dies were excluded, unless an English language abstract
provided sufficient detail on patients and outcomes.
Critical appraisal and synthesis
Information from the studies was extracted by two
reviewers using a pre-tested data abstraction form and a
set of decision rules. The form contained elements for
examining the purpose and methods of each study
(Table 2). Missing data were sought from study authors.
Consensus between reviewers on the information col-
lected was assessed using the Kappa statistic.
T h eq u a l i t yo fe a c hs t u d yw a sa l s oa s s e s s e db yt w o
reviewers using the Oxford Centre for Evidence-based Med-
icine Levels of Evidence [12]. Discrepancies were resolved
through consensus and Kappa scores were calculated.
Data analysis
Qualitative
Information was summarized in tabular form to more
easily identify trends or patterns in findings reported
across studies.
Quantitative
Results from individual studies were pooled using
weighted mean values to generate summary estimates
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analyses were conducted in accordance with intention-
to-treat principles (i.e., patients were analyzed in the
groups to which they were originally allocated, regard-
less of whether or not they received the assigned
treatment).
Results
Description of studies
Over 400 potentially relevant papers were selected from
the literature search results and reviewed for inclusion
(Figure 1). Of these, 99 papers, reporting on 101 sepa-
rate studies and 3042 patients, met the inclusion criteria.
Descriptions of each study are presented in Additional
f i l e s1 ,2 ,3 ,4 ,5 ,6 ,7 ,a n d8 .Ab r e a k d o w no fs t u d i e sb y
the type of intervention and study design is presented in
Table 3.
Quality of studies
T h eq u a l i t yo ft h ee v i d e n c er e v i e w e dw a sg e n e r a l l yl o w .
Only 12 studies were comparative (Table 3), and of
these, 5 were cohort studies with uncontrolled allocation
of patients to each treatment group. Details of the study
methods used were sparse, with missing information or
inconsistent reporting of outcomes across patient
groups.
Seven randomized controlled trials (RCTs) were iden-
tified, but these compared only APC with PDT (4 trials
[13-16]), or APC with MPEC (2 trials [17,18]), or RFA
with sham procedure (1 trial [19]). Sample sizes were
small and follow-up times were short. Because the types
of patients and the treatment protocols (e.g., number of
treatment sessions) varied a meta-analysis was not used.
In the non-comparative studies of endoscopic techni-
ques (single arm clinical trials or case series), the treat-
ment protocols (e.g., number of treatment sessions),
outcomes measured, and follow-up times also differed.
There were few studies that reported long-term follow
up results, and so pooling of study outcome and adverse
event results is limited. As well, the number of treat-
ment sessions provided before outcomes were measured
was not often reported, although in many cases, it was
after a single ablation. Patients often received interven-
tions in addition to the study treatment. For example, in
most studies EMR was performed during endoscopy to
confirm the diagnosis of dysplasia. In addition, if one
treatment failed to eradicate the dysplasia another treat-
ment would typically be administered. The analyses of
outcomes did not usually account for the effects of
these additional interventions.
Safety
Adverse events reported for individual studies of eso-
phagectomy and endoscopic alternatives are summarized
in Table 4 and Additional file 9. The pooled estimates
for esophagectomy and endoscopic treatments are
Table 1 Criteria for including studies in this review
Parameter Inclusion criteria Exclusion criteria
￿ Randomized or controlled (e.g., pseudo-randomized or quasi-randomized)
trials
Study design ￿ Non-randomized clinical trials ￿ Editorials & opinion pieces
￿ Retrospective, prospective, or concurrent cohort studies ￿ Review articles
￿ Case or clinical series
Participants ￿ Patients diagnosed with BE ￿ Patients diagnosed with esophageal cancer or other
conditions
￿ PDT
Interventions ￿ Esophagectomy
￿ EMR
￿ Other endoscopic treatments (cryoablation, laser ablation, APC, MPEC, RFA,
thermocoagulation)
Comparators ￿ Same as interventions above
Outcomes ￿ Not used for inclusion/exclusion due to heterogeneity of data
Table 2 Summary of elements in the data abstraction form
Parameter Description of information collected
Cancer/cell type BE; dysplasia
Study design Setting; study type; treatment(s) used; length of follow-up
Patients Number of patients by treatment group; age; gender; length of Barrett’s; inclusion/exclusion criteria; prior treatments
Intervention Details of the treatment; number of patients who underwent each treatment; co-interventions
Outcomes Complete and partial response; survival; recurrence; progression to cancer; reduction in length of Barrett’s; adverse events
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included, and 4 were excluded.
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Page 4 of 12shown in Tables 5 and 6. There were 2 deaths [20,21]
attributed to esophagectomy among the 170 patients
who underwent the procedure (a mortality rate of 1.2%).
(The surgical studies employed various approaches; in
some studies, the actual approach was not specified, and
in the others, a number of approaches were used (i.e.,
t h ep a t i e n t sd i dn o ta l lh a v et h es a m es u r g i c a l
approach). Therefore, data could not be analysed
according to individual surgical approaches). In contrast,
1 death [13] was reported in the 2831 patients who
received endoscopic treatment (0.04%). This death was
due to cardiac arrhythmia in a patient who received
PDT with aminolevulinic acid (ALA) at a dose of
60 mg/kg of body weight [13].
In the studies that reported bleeding complications
following endoscopic treatments, 4 of 2218 patients
(0.2%) experienced bleeding requiring transfusions: 1
after PDT [22], 2 after APC [23] and 1 after laser abla-
tion [24]. Strictures were most frequently reported with
porfimer sodium PDT (18.5%), followed by laser abla-
tion (4.4%) and APC (2.9%) (Table 6). Although there
were no perforations reported in the PDT studies that
used a single photosensitizer (reported in Table 6), there
was a perforation reported in the Prasad et al study
[21], which compared esophagectomy with PDT using
two different photosensitizers. Since it was impossible to
separate the patients according to the photosensitizer
type, this study was not included in Table 6. Patients
experiencing dysphagia and odynophagia varied across
the treatment modalities, but were highest with MPEC
(Table 6). Photosensitivity following PDT was more
common with porfimer sodium (26.4%) than with ALA
(ranging from 0% to 13.6%). However, in a small series
of 5 patients who received hematoporphyrin derivative
(HpD), 40% experienced photosensitivity reactions
(Table 6).
The most commonly reported adverse events asso-
ciated with esophagectomy were anastomotic leaks
(9.4%), strictures (5.3%), wound infections (4.1%) and
pulmonary complications (4.1%) (Table 5). None of the
studies discussed the relationship between adverse
events and clinician experience.
Efficacy or effectiveness
Values reported for the complete eradication of BE or
high grade dysplasia (HGD) with endoscopic treatments
are presented in Additional files 10 and 11. Pooled
values for complete eradication of BE and HGD with
endoscopic treatments are presented in Table 7. For the
purposes of this analysis, only the complete eradication
rates reported in the individual studies within the first 3
months after ablation were included. Few studies pro-
vided enough data on longer follow up periods to make
pooling of the data meaningful. The studies did not all
report the number of ablations that were provided
before the outcome was measured, and in many cases,
the authors reported a range of number of treatments.
Results of 2 of the 3 RCTs of PDT (with ALA) versus
APC in patients with BE demonstrated a significant dif-
ference in complete eradication, favouring APC over
PDT [13,14]. Specifically, the complete eradication rates
in the APC group were almost double that of the PDT
group (Additional file 10). In the third RCT, complete
eradication rates were not reported for both groups of
patients [16].
Two RCTs reported on complete eradication of HGD
[15,19]. In the RCT which compared PDT using porfi-
mer sodium to APC, there was no statistically significant
difference in complete eradication rate between treat-
ment groups at 4 months follow-up [15]. In the RCT
which compared RFA with sham procedure, there was a
statistically significant difference in complete eradication
Table 3 Numbers of included studies and patients
Treatment Number of studies Comparative studies Non-comparative studies Number of patients
Endoscopic PDT 37 5[13-16,25] 32[22,26-54] 1028
APC 26 7[13-18,55] 19[23,56-73] 792
Cryoablation 2 0 2[74,75] 31
Combined EMR & PDT 2 1[25] 1[76] 6
Thermocoagulation 1 0 1[77] 13
EMR 6 2[20,25] 4[78-81] 38
Laser ablation 7 0 7[24,82-87] 91
MPEC 6 2[17,18] 4[88-90] 118
RFA 16 2[19,92] 14[93-105] 714
Total* 95* 11* 86 2831
Surgical Esophagectomy 8 3[21,57,79] 5[109-111]112 211
Total* 101* 12* 91 3042
Notes: (1) APC (argon plasma coagulation), EMR (endoscopic mucosal resection), MPEC (multipolar electrocoagulation), PDT (photodynamic therapy), RFA
(radiofrequency ablation) (2) *9 comparative studies are reported in both intervention groups (e.g., APC and PDT), thus the number of separate comparative trials
is less than the sum of entries in the column.
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Adverse event rates (No. of patients who suffered adverse events/No. of patients who received esophagectomy)
Study No. of
patients
A.leak* CV compl.* Del. gastric
emptying*
Mortality Pneumon.* Pulm.
compl.*
Pulm.
embol.*
Small bowel
perf.*
Strictures Wound
infec.*
Comparative studies
Prasad GA, et al. (2007)[21] 70 0% (0/70) 0% (0/70) 0% (0/70) 1.4% (1/70) 0% (0/70) 0% (0/70) 0% (0/70) 0% (0/70) 12.9% (9/70) 0% (0/70)
Reed MF, et al. (2005)[20] 49 4.1% (2/49) 0% (0/49) 0% (0/49) 2.0% (1/49) 0% (0/49) 0% (0/49) 0% (0/49) 0% (0/49) 0% (0/49) 0% (0/49)
Thomas T, et al. (2005)[55] 8 Not reported Not reported Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not reported Not
reported
Not
reported
Non-comparative studies
Ferguson MK, et al. (1997)[107] 15 73.3% (11/15) 20.0% (3/15) 0% (0/15) 0% (0/15) 0% (0/15) 26.7% (4/15) 0% (0/15) 0% (0/15) 0% (0/15) 33.3% (5/15)
Nguyen NT, et al. (2000)[108] 12 0% (0/12) 0% (0/12) 25.0% (3/12) 0% (0/12) 0% (0/12) 16.7% (2/12) 0% (0/12) 8.3% (1/12) 0% (0/12) 8.3% (1/12)
Romagnoli R (2003)[109] 33 Not reported Not reported Not
reported
Not
reported
Not
reported
Not
reported
Not
reported
Not reported Not
reported
Not
reported
Sujendran V, et al. (2005)[110] 17 17.6% (3/17) 0% (0/17) 0% (0/17) 0% (0/17) 17.6% (3/17) 5.9% (1/17) 0% (0/17) 0% (0/17) 0% (0/17) 0% (0/17)
Thomson BNJ & Cade RJ (2003)
[111]
7 0% (0/7) 0% (0/7) 0% (0/7) 0% (0/7) 0% (0/7) 0% (0/7) 14.3% (1/7) 0% (0/7) 0% (0/7) 14.3% (1/7)
Pooled total 211 9.4% (16/170)
0-73.3%‡
1.8% (3/170)
0-20.0%‡
1.8% (3/170)
0-25.0%‡
1.2% (2/170)
0-2.0%‡
1.8% (3/170)
0-17.6%‡
4.1% (7/170)
0-26.7%‡
0.6% (1/170)
0-14.3%‡
0.6% (1/170)
0-8.3%‡
5.3% (9/170)
0-12.9%‡
4.1% (7/170)
0-33.3%‡
Notes: (1) *A.leak (anastomotic leak), CV compl. (cardiovascular complication), Del. gastric emptying (delayed gastric emptying), Pneumon. (pneumonia), Pulm. compl. (pulmonary complication), Pulm. embol.
(pulmonary embolsim), Small bowel perf. (small bowel perforation), Wound infec. (wound infection) (2) ‡Ranges of the adverse event rates post-esophagectomy for the included studies
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2rate between the group treated by RFA (81.0%) and the
control group (19.0%) at 12 months follow-up [19].
Discussion
Endoscopic therapies appear to be viable and effective
treatment options for Barrett’s esophagus with high
grade dysplasia. All of the endoscopic therapies are safer
(i.e., have fewer adverse events and lower mortality
rates) than esophagectomy.
Some key questions regarding these treatments cannot
yet be answered and further studies are needed to
address these “gaps in the evidence”. In particular, we
need studies:
￿ to confirm the long-term safety of these endo-
scopic treatments, and their effectiveness in prevent-
ing esophageal cancer
￿ to identify the endoscopic treatments (or combina-
tions of treatments) that produce the best outcomes
￿ to determine whether or not continued drug ther-
apy (e.g., with proton pump inhibitors) or surgery
(e.g., fundoplication) to treat gastroesophageal reflux
is beneficial after endoscopic treatment of dysplasia
￿ to provide guidance on the optimal frequency of
post-treatment endoscopic surveillance for patients
with Barrett’s esophagus
￿ to measure patient preferences for, and quality of
life after, the different endoscopic treatments.
Conclusions
Given the current limitations in the evidence (in terms
of both quantity and quality of studies), it was not possi-
ble to conclusively determine the comparative effective-
ness of the different endoscopic treatments. However,
the evidence suggests that endoscopic treatments are
safe and reasonably effective alternatives to esophagect-
omy for patients with Barrett’s esophagus with high
grade dysplasia. Endoscopic treatments have the addi-
tional advantages of being outpatient procedures with
shorter recovery times. They also provide treatment
options for patients who would not be considered for
esophagectomy due to other health conditions.
Of the endoscopic therapies, photosensitivity is only an
issue with photodynamic therapy (more so with porfimer
sodium than with other photosensitizing agents). Pre-
venting adverse events due to photosensitivity requires
patient and caregiver compliance and education.
There appears to be little difference between the
endoscopic technologies in terms of overall efficacy.
Patient and physician preferences, and the local avail-
ability of the different technologies will likely guide deci-
sion making. A combination of different endoscopic
treatments may provide the best outcomes. Given that
relatively few patients need these treatments each year,
offering them at specialized centres will concentrate
clinical expertise and be the most cost-effective
approach.
Additional material
Additional file 1: Studies of photodynamic therapy (PDT) for
Barrett’s esophagus with/without dysplasia. Details of study and
patient characteristics, outcomes and study quality of the included
studies of PDT for BE with/without dysplasia are presented in Additional
file 1.
Additional file 2: Studies of argon plasma coagulation (APC) for
Barrett’s esophagus with/without dysplasia. Details of study and
patient characteristics, outcomes and study quality of the included
studies of APC for BE with/without dysplasia are presented in Additional
file 2.
Additional file 3: Studies of cryoablation, combined endoscopic
mucosal resection (EMR) and photodynamic therapy (PDT), and
thermocoagulation for Barrett’s esophagus with/without dysplasia.
Details of study and patient characteristics, outcomes and study quality
of the included studies of cryoablation, combined EMR and PDT, and
thermocoagulation for BE with/without dysplasia are presented in
Additional file 3.
Additional file 4: Studies of endoscopic mucosal resection (EMR) for
Barrett’s esophagus with/without dysplasia. Details of study and
patient characteristics, outcomes and study quality of the included
studies of EMR for BE with/without dysplasia are presented in Additional
file 4.
Additional file 5: Studies of laser ablation for Barrett’s esophagus
with/without dysplasia. Details of study and patient characteristics,
outcomes and study quality of the included studies of laser ablation for
BE with/without dysplasia are presented in Additional file 5.
Additional file 6: Studies of multipolar electrocoaguation (MPEC) for
Barrett’s esophagus with/without dysplasia. Details of study and
patient characteristics, outcomes and study quality of the included
studies of MPEC for BE with/without dysplasia are presented in
Additional file 6.
Table 5 Summary of adverse events post-esophagectomy
A. leak* CV
compl.*
Del. gastric emptying* Mortality Pneumon.* Pulm.
compl.*
Pulm.
embol.*
Small
bowel
perf.*
Strictures Wound
infec.*
9.4%* 1.8%* 1.8%* 1.2%* 1.8%* 4.1%* 0.6%* 0.6%* 5.3%* 4.1%*
16/170‡ 3/170‡ 3/170‡ 2/170‡ 3/170‡ 7/170‡ 1/170‡ 1/170‡ 9/170‡ 7/170‡
0 -73.3%† 0 -20.0%† 0 - 25.0%† 0 - 2.0%† 0 - 17.6%† 0 - 26.7%† 0 - 14.3%† 0 - 8.3%† 0 - 12.9%† 0 - 33.3%†
Notes: (1) *A.leak (anastomotic leak), CV compl. (cardiovascular complication), Del. gastric emptying (delayed gastric emptying), Pneumon. (pneumonia), Pulm.
compl. (pulmonary complication), Pulm. embol. (pulmonary embolism), Small bowel perf. (small bowel perforation), Wound infec. (wound infection) (2) *Adverse
event rates post-esophagectomy, ‡ No. of patients who suffered adverse events/No. of patients who received esophagectomy, † Ranges of the adverse event
rates post-esophagectomy for the included studies
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Adverse event rates post- endoscopic treatments (No. of patients who suffered adverse events/No. of patients who received treatments)
Study Dysphagia Photosen.* Stricture Perfor.* Odynoph.* Bleed.*
PDT
ALA 15 mg/kg 15.4% (2/13) 13.6% (3/22) 0-23.1%† 0% (0/22) 0% (0/22) 0% (0/22) 0% (0/22)
ALA 30 mg/kg 0% (0/106) 5.7% (6/106) 0-14.7%† 0% (0/106) 0% (0/106) 0.9% (1/106) 0-2.9%† 0%
(4) (0/90)
ALA 40 mg/kg 0% (0/22) 0% (0/22) 0% (0/22) 0% (0/22) 0% (0/22) 0% (0/22)
ALA
(1) 60 mg/kg 2.7% (4/148) 0-40.0%† 4.3% (6/140) 0-75.0%† 1.4% (2/148) 0-12.5%† 0% (0/148) 16.2% (24/148) 0-92.3%† 0.9%
(4) (1/115) 0-7.7%†
HpD 1.5 mg/kg 0% (0/59) 40.0% (2/5) 0% (0/59) 0% (0/59) 0% (0/5) 0% (0/59)
mTHPC 0.15 mg/kg -** -** -** -** -** -**
Porfimer sodium(2 mg/kg) 6.6% (26/394) 0-18.8%† 26.4% (104/394) 0-68.8%† 18.5% 73/394 0-37.5%† 0% (0/394) 0% (0/394) 0% (0/394)
Other endoscopic treatments
APC 3.8% (27/719) 0-100%† 0% (0/719) 2.9% (21/719) 0-23.1%† 0.3% (2/719) 0-3.4%† 11.8% (85/719) 0-94.1%† 0.4%
(2) (3/719) 0-3.9%†
Cryoablation 9.1% (1/11) 0% (0/11) 0% (0/11) 0% (0/11) 0% (0/11) 0% (0/11)
Combined EMR & PDT 0% (0/6) 0% (0/6) 0% (0/6) 0% (0/6) 0% (0/6) 0% (0/6)
Thermocoagualtion 0% (0/13) 0% (0/13) 0% (0/13) 0% (0/13) 0% (0/13) 0% (0/13)
EMR 0% (0/32) 0% (0/32) 0% (0/32) 0% (0/32) 0% (0/32) 9.4% (3/32) 0-25.0%†
Laser ablation 0% (0/68) 0% (0/68) 4.4% (3/68) 0-12.5%† 1.5% (1/68) 0-4.8%† 0% (0/68) 1.5%
(5) (1/68) 0-4.8%†
MPEC 19.4% (18/93) 0-40.7%† 0% (0/93) 1.1% (1/93) 0-3.7%† 0% (0/93) 16.1% (15/93) 0-40.7%† 1.1% (1/93) 0-10.0%†
RFA 1.4% (8/574) 0-23.1%† 0% (0/574) 1.9% (11/574) 0-6.1%† 0% (0/574) 0.5% (3/574) 0-23.1%† 0.5% (3/574) 0-1.6%†
Notes: (1) 1 patient suffered cardiac arrhythmia resulting in sudden death [13]. (2) 2 patients required blood transfusions. (3) ALA (aminolevulinic acid), APC (argon plasma coagulation), EMR (endoscopic mucosal
resection), HpD (hematoporphyrin derivative), MPEC (multipolar electrocoagulation), mTHPC (meta-tetrahydroxyphenylchlorin), PDT (photodynamic therapy), RFA (radiofrequency ablation) (4) 1 patient required blood
transfusion, but it cannot be definitely attributed to the 30 mg/kg treatment or the 60 mg/kg ALA treatment. (5) 1 patient required blood transfusion. (6) * Photosen. (photosensitivity), Perfor. (perforation), Odynoph.
(odynophagia), Bleed. (bleeding), ** - (pooled total not available), † Ranges of the adverse event rates post-endoscopic treatments for the included studies
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2Additional file 7: Studies of radiofrequency ablation (RFA) for
Barrett’s esophagus with/without dysplasia. Details of study and
patient characteristics, outcomes and study quality of the included
studies of RFA for BE with/without dysplasia are presented in Additional
file 7.
Additional file 8: Studies of esophagectomy for Barrett’s esophagus
with/without dysplasia. Details of study and patient characteristics,
outcomes and study quality of the included studies of esophagectomy
for BE with/without dysplasia are presented in Additional file 8.
Additional file 9: Studies of adverse events (endoscopic treatments).
Adverse events reported for individual studies of endoscopic alternatives
are presented in Additional file 9.
Additional file 10: Studies of complete eradication of Barrett’s
esophagus (endoscopic treatments). Values reported for the complete
eradication of BE with endoscopic treatments are presented in Additional
file 10.
Additional file 11: Studies of complete eradication of high grade
dysplasia (endoscopic treatments). Values reported for the complete
eradication of HGD with endoscopic treatments are presented in
Additional file 11.
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